Comparative Pharmacology
Head-to-head clinical analysis: OLANZAPINE AND FLUOXETINE HYDROCHLORIDE versus ZYPREXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OLANZAPINE AND FLUOXETINE HYDROCHLORIDE versus ZYPREXA.
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE vs ZYPREXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). The combination modulates serotonergic and dopaminergic pathways to treat depressive episodes in bipolar I disorder.
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, with higher affinity for 5-HT2A than D2. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic M1 receptors.
Olanzapine 6 mg / fluoxetine 25 mg orally once daily in the evening, with dose adjustments based on response and tolerability.
5-10 mg orally once daily; may increase by 5 mg/day at intervals of at least 1 week; maximum 20 mg/day.
None Documented
None Documented
Olanzapine: 30 h (young adults); 50 h (elderly). Fluoxetine: 4-6 days (single dose), 4-6 days (norfluoxetine); longer with chronic dosing (up to 6-8 weeks to steady state). Clinical context: drug accumulates over weeks.
Terminal elimination half-life ~30 hours (range 21–54 h) in adults, allowing once-daily dosing; steady-state reached in ~5–7 days. Half-life prolonged in elderly, females, and hepatic impairment.
Olanzapine: ~57% renal (metabolites), ~30% fecal. Fluoxetine: ~80% renal (metabolites, mainly norfluoxetine), ~15% fecal.
Primarily hepatic metabolism via CYP1A2 and CYP2D6; ~7% excreted unchanged in urine, ~57% in urine as metabolites, ~30% in feces (mostly metabolites).
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic